Dicembre 16, 2025 Claris Ventures Announces First Closing of Claris Biotech II Turin, Italy – December 16th, 2025 – Haptena Therapeutics, a newly formed biotechnology company […] Haptena launches with €3 million seed financing from Claris Ventures to develop innovative treatments for KRAS-driven cancers
Aprile 23, 2025 Claris Ventures Announces First Closing of Claris Biotech II Turin – April 23, 2025 – Claris Ventures today announced the first closing […] Claris Ventures Announces First Closing of Claris Biotech II
Maggio 14, 2024 Claris Ventures and Exor Ventures Team Up for the Development of Innovative Drugs in Italy Turin, May 14, 2024 – Claris Ventures […] Claris Ventures and Exor Ventures Team Up for the Development of Innovative Drugs in Italy
Marzo 6, 2024 CLARIS’S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC’S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES Hamburg, Germany, and Turin, […] Claris Ventures and Evotec Forge Powerful Partnership to Fast-Track Portfolio Programs Into Clinical Advancement
Dicembre 21, 2023 Newly launched TCR company ALKemist Bio announces a €6.9M Investment Round to develop first-in-class TCR Cell Therapy for ALK-Positive Tumors Turin, Italy […] Newly launched TCR company ALKemist Bio announces a €6.9M Investment Round to develop first-in-class TCR Cell Therapy for ALK-Positive Tumors
Febbraio 27, 2023 Claris Ventures appoints pharmaceutical industry veteran Michael Hodges as a Partner Claris Ventures appoints pharmaceutical industry veteran Michael Hodges as a Partner […] Claris Ventures appoints pharmaceutical industry veteran Michael Hodges as a Partner
Gennaio 28, 2023 Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform Sibylla Biotech Raises […] Sibylla Biotech raises €23 Million Series A
Marzo 31, 2022 Iama Therapeutics Raises €8 Million Series A IAMA THERAPEUTICS RACCOGLIE 8 MILIONI DI EURO PER LO SVILUPPO DI UN NUOVO CANDIDATO FARMACO […] Iama therapeutics raises €8 Million Series A
Marzo 24, 2022 Heqet Therapeutics raises €8m to advance its RNA-based therapeutic program for cardiac regeneration March 23rd, 2022 – Heqet Therapeutics, a King’s College London […] Hequet Therapeutics raises €8 million
Marzo 24, 2022 Kither Biotech Raises €18.5 Million Series B Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive […] Kither Biotech Raises €18.5 Million Series B
Luglio 21, 2021 Claris Ventures announces final closing: €85m ($100m) for Italian Biotech Fund oversubscription, one year after its launch by the Turin based SGR […] Claris Biotech I Final Closing
Marzo 9, 2021 NeoPhore Announces $21m Financing to Advance DNA Mismatch Repair Pipeline Round led by Claris Ventures with 2Invest, 3B Future Health Fund and […] NeoPhore Announces $21m Financing to Advance DNA Mismatch Repair Pipeline
Settembre 1, 2020 Primo closing a quota €30m per Claris Biotech I, fondo biotech promosso da Claris Ventures SGR Torino, 1 settembre 2020 – Claris […] CLARIS VENTURES LANCIA UN FONDO DEDICATO AL BIOTECH ITALIANO
Aprile 7, 2020 La rivista Prisma dedica un articolo a Claris Ventures La rivista Prisma nel mese di aprile dedica un articolo a Claris Ventures. […] Claris Ventures sulla rivista Prisma di Aprile
